0:32
In a 2020 study conducted at Massachusetts General Hospital, researchers investigated the effect of the growth‑hormone‑releasing peptide tesamorelin on hepatic steatosis. Participants received tesamorelin for 12 months, and liver biopsies taken before and after treatment showed a substantial 37 % reduction in fatty liver deposits. The presenter also highlighted that excess liver fat poses a greater health risk than visceral adiposity, underscoring the clinical relevance of the findings. The segment is delivered in a conversational style aimed at a general‑interest audience.
